Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Advanced or Metastatic Solid Tumor Clear all

Completed Phase 1Phase 2 Interventional

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NCT03965845

View directory record Official record

Conditions: Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
Interventions: Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance]; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Santa Monica, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Source: ClinicalTrials.gov public record

Updated Sep 18, 2022 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

NCT00127829

View directory record Official record

Conditions: Tumors
Interventions: Gefitinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • Palm Springs, California

Source: ClinicalTrials.gov public record

Updated Apr 22, 2009 · Synced May 21, 2026, 10:17 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

View directory record Official record

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469

View directory record Official record

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Source: ClinicalTrials.gov public record

Updated Mar 29, 2023 · Synced May 21, 2026, 10:17 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional Results available

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

NCT02650986

View directory record Official record

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
Interventions: Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes; Drug · Other · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 12 Years and older

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Jun 16, 2025 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional Results available

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

NCT01449370

View directory record Official record

Conditions: Metastatic Solid Tumors
Interventions: TAK-117; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan • Dallas, Texas

Source: ClinicalTrials.gov public record

Updated Mar 8, 2017 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

NCT01986166

View directory record Official record

Conditions: Neoplasms
Interventions: Cobimetinib, MEHD7945A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Source: ClinicalTrials.gov public record

Updated Jul 17, 2016 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

NCT05639751

View directory record Official record

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions: PRT3789, Docetaxel; Drug
Lead sponsor: Prelude Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more

Source: ClinicalTrials.gov public record

Updated Oct 15, 2025 · Synced May 21, 2026, 10:17 PM EDT

Suspended Phase 1 Interventional

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

NCT05155332

View directory record Official record

Conditions: Solid Tumors
Interventions: BI 1831169, anti-PD-1 antibody; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 7 more

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 21, 2026, 10:17 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

NCT06885034

View directory record Official record

Conditions: Gastrointestinal Neoplasms
Interventions: GSK5764227; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Los Alamitos, California • Whittier, California • New York, New York + 4 more

Source: ClinicalTrials.gov public record

Updated Nov 17, 2025 · Synced May 21, 2026, 10:17 PM EDT

Terminated Phase 1 Interventional Results available

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

NCT04642365

View directory record Official record

Conditions: Solid Tumors
Interventions: RO7296682, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated May 20, 2025 · Synced May 21, 2026, 10:17 PM EDT

Active, not recruiting Phase 1 Interventional

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614

View directory record Official record

Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Interventions: BBI-355, Erlotinib, Futibatinib, BBI-825; Drug
Lead sponsor: Boundless Bio, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more

Source: ClinicalTrials.gov public record

Updated Jan 22, 2026 · Synced May 21, 2026, 10:17 PM EDT

Recruiting Phase 1 Interventional

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

NCT04762641

View directory record Official record

Conditions: Advanced Solid Tumor
Interventions: ABL503; Drug
Lead sponsor: ABL Bio, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 2 more

Source: ClinicalTrials.gov public record

Updated Feb 5, 2025 · Synced May 21, 2026, 10:17 PM EDT

Recruiting Phase 1 Interventional

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

NCT05948865

View directory record Official record

Conditions: Cancer, Cancer, Lung
Interventions: CPO301; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Newport Beach, California • Santa Monica, California + 8 more

Source: ClinicalTrials.gov public record

Updated Mar 19, 2026 · Synced May 21, 2026, 10:17 PM EDT

Terminated Phase 1 Interventional

Study of ORIC-101 in Combination With Anticancer Therapy

NCT03928314

View directory record Official record

Conditions: Solid Tumor
Interventions: ORIC-101, Nab-paclitaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Source: ClinicalTrials.gov public record

Updated Dec 14, 2023 · Synced May 21, 2026, 10:17 PM EDT

Completed Not applicable Interventional

PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer

NCT02088775

View directory record Official record

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Stage D Adult Primary Liver Cancer (BCLC), Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PET scan, CT Scan, hepatic artery embolization; Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 15, 2024 · Synced May 21, 2026, 10:17 PM EDT

Not listed Phase 1 Interventional

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04859777

View directory record Official record

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Interventions: MPT-0118, MPT-0118 + pembrolizumab; Drug
Lead sponsor: Monopteros Therapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Santa Monica, California • Boston, Massachusetts • New York, New York + 2 more

Source: ClinicalTrials.gov public record

Updated Sep 15, 2021 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866

View directory record Official record

Conditions: AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions: Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more

Source: ClinicalTrials.gov public record

Updated Aug 8, 2024 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1Phase 2 Interventional

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839

View directory record Official record

Conditions: Solid Tumor, Adult
Interventions: DF9001, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more

Source: ClinicalTrials.gov public record

Updated Oct 28, 2025 · Synced May 21, 2026, 10:17 PM EDT

Completed Phase 1 Interventional

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT01527136

View directory record Official record

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: entolimod, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Jul 21, 2022 · Synced May 21, 2026, 10:17 PM EDT

Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935

View directory record Official record

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Source: ClinicalTrials.gov public record

Updated May 24, 2025 · Synced May 21, 2026, 10:17 PM EDT

Active, not recruiting Phase 2 Interventional

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT05103358

View directory record Official record

Conditions: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 12 Years and older

Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 159
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more

Source: ClinicalTrials.gov public record

Updated Jun 2, 2024 · Synced May 21, 2026, 10:17 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734

View directory record Official record

Conditions: Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions: ALE.P03; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older

Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 21, 2026, 10:17 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

NCT05572684

View directory record Official record

Conditions: Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions: NC410, pembrolizumab; Drug
Lead sponsor: NextCure, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more

Source: ClinicalTrials.gov public record

Updated Dec 15, 2024 · Synced May 21, 2026, 10:17 PM EDT